Key result
MiStent sirolimus-eluting stent demonstrates potential clinical performance driven by ultra-thin struts and controlled drug release.
Why the study?
Recent clinical trials have demonstrated the potential performance of the novel MiStent sirolimus-eluting stent, warranting an overview of its design, technological features, and clinical performance.
The MiStent sirolimus-eluting stent features ultra-thin struts, a bioresorbable polymer, and controlled drug release, representing a novel state-of-the-art DES technology.
Answers are grounded in this paper and cite their sources.
MiStent shows promise but should not alter current DES selection; leaves open need for randomized comparisons.
Drug-eluting stents (DES) have been developed over recent decades and the implantation of DES is the standard of care in contemporary percutaneous coronary intervention for patients with coronary artery disease. The MiStent sirolimus-eluting stent has several unique features; ultra-thin (64 μm) struts, a bioresorbable polymer and a controlled drug release from microcrystalline sirolimus as a reservoir embedded in the vessel wall. Results of recent clinical trials demonstrated the potential performance of this state-of-the-art DES. In the present review, we provide an overview of the development of DES, in particular the design and performance of the novel MiStent sirolimus-eluting stent from technological and clinical points of view and discuss the potentials of this new type of DES.
No takes yet. Share an insight, caveat, or question.
Ono et al. (2020) conducted a review in Coronary artery disease. MiStent sirolimus-eluting stent was evaluated. The MiStent sirolimus-eluting stent features ultra-thin struts, a bioresorbable polymer, and controlled drug release, demonstrating potential performance in recent clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: